CTLA4 and carcinoma: Particularly, therapies involving immune checkpoint inhibitors (ICIs) have shown remarkable and long-lasting clinical outcomes in some advanced carcinoma, represented by programmed death protein-1 (PD-1) or its ligand (PD-L1) antibody and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody therapies.